|
|
 |
|
Viewing report
|
|
|
|
RNAi: Broad Application, Expansive Opportunity, 2nd Edition
Drug and Market Development Publishing, Jan 2005, Pages: 326
RNAi is the hottest topic in biotechnology and is positioned to revolutionize research and drug discovery. The drug discovery market based on RNAi is projected to be $650 million in 2005 and $1 billion by 2010. Don't miss out on your share of this growing market! The increasing demand for target validation and the large number of new potential targets has augmented the need and importance of RNAi in sorting through the possibilities.
The future is bright for this technology in that it may supplant or complement crucial existing technologies such as antisense and knockout models. As the first drugs are commercialized there will be an even greater interest in this exciting new technology.
- Receive a thorough analysis of trends in the RNAi technology market including strengths, weaknesses and opportunities through extensive qualitative and quantitative research.
- Read detailed overviews of current Phase I clinical trials for RNAi based therapeutics.
- Comprehensive analysis of key market drivers such as the cost of drug development as well as an overview of diseases presenting market opportunities for RNAi.
- Examine in depth profiles of leading companies who develop therapeutics, and routinely utilize target validation within the rapidly expanding RNAi technology marketplace.
- This report is a must read for Research, Marketing, and Business Development Executives within the Pharmaceutical, Molecular Biology, ad Cell Biology fields.
About The Author
Dr. Edward Weck Dr. Weck has extensive experience in industry, technology transfer, and as a consultant. Following work in Germany and California cloning starch control genes, he worked on vectors for corn transformation. This culminated in participation in the development transgenic Bt corn at Northrup King (now Syngenta Seeds). Dr. Weck has recently worked in assessing biotechnologies for transfer to client companies with Interlink Biotechnology. He has authored reports on Transgenic Plants, Transgenic Animals and Enzymes for IBCUSA. He played an important role in transferring plant breeding and genetics technology to developing countries for the FAO/IAEA Joint Division of Nuclear Techniques in Food and Agriculture in Vienna, Austria (1995-1997). Dr. Weck received his Ph.D. in Chemistry from the University of Arkansas in 1980, doing his dissertation work on small molecules involved in tumor regression in chickens. Dr Weck is currently a registered patent agent and Biotechnology consultant at BioTec Information in Northfield, MN and is inhis last year of law school at William Mitchell College of Law.
Customers who bought this item also bought
RNAi - Technologies, Markets and Companies
Outlook for RNAi, 2007: siRNA and miRNA in Biology, Diagnostics and Therapeutics
RNAi 2008
The Outlook For RNAi: Accelerating Drug Discovery and the Development of RNAi Therapeutics
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
RNAi Therapeutics 2008 Market Report
The Future of RNAi Therapeutics: Drug Pipelines and Prospects
Realizing the Promise of Therapeutic RNAi: Emerging Strategies for RNAi Delivery
Advances in RNAi--A Global Technology Assessment (Technical Insights)
Emerging Drug Discovery Technologies: Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi
Alnylam & Roche RNAi Therapeutics Strategic Alliance Agreement Call - Alnylam Pharmaceuticals, Inc. - Earnings Transcript
U.S. RNAi Markets
|
|
|
|
